Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma.

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2021-03-25 DOI:10.1080/23723556.2021.1902250

Richa Rathore, Brian Van Tine

引用次数: 0

Abstract

The rate-limiting enzyme of serine biosynthesis, 3-phosphoglycerate dehydrogenase (PHGDH), contributes to rapid growth and proliferation when it is overexpressed in cancer. We recently described the metabolic adaptations that occur upon PHGDH inhibition in osteosarcoma. PHGDH inhibition causes metabolite accumulation that activates the mechanistic target of rapamycin (mTOR) signaling, sensitizing osteosarcoma to non-rapalog mTOR inhibition.

查看原文本刊更多论文

靶向单碳代谢需要mTOR抑制:骨肉瘤的新治疗方法

丝氨酸生物合成的限速酶，3-磷酸甘油酸脱氢酶(PHGDH)，当它在癌症中过度表达时，有助于快速生长和增殖。我们最近描述了骨肉瘤中PHGDH抑制后发生的代谢适应。PHGDH抑制导致代谢物积累，激活雷帕霉素(mTOR)信号传导的机制靶点，使骨肉瘤对非雷帕霉素mTOR抑制敏感。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.